Reliability and validity of the M. D. Anderson Symptom Inventory–Spine Tumor Module
Terri S. Armstrong(The University of Texas MD Anderson Cancer Center), Charles S. Cleeland(The University of Texas MD Anderson Cancer Center), Ibrahima Gning(The University of Texas MD Anderson Cancer Center), Jeffrey S. Weinberg(The University of Texas MD Anderson Cancer Center), Laurence D. Rhines(Memorial Sloan Kettering Cancer Center), Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Gisela Sanchez‐Williams(The University of Texas MD Anderson Cancer Center), Allen W. Burton(Abbott (United States)), Elizabeth Vera‐Bolanos(The University of Texas MD Anderson Cancer Center), Victor A. Levin(Orbus Therapeutics (United States)), Tito R. Mendoza(The University of Texas MD Anderson Cancer Center)
Cited by 45
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k